Építés alatt – nem éles oldal
Belépés
BefejeződöttFázis nélkül

A Pilot Study of Transcranial Magnetic Stimulation Plus Episodic Future Thinking for Methamphetamine Use Disorder

A legfontosabb adatok

Ki végzi
The University of Texas Health Science Center, Houston
Hol
Houston (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Befejeződött
Résztvevők
14 fő vett részt
Kezdés
2025. márc. 31.
Befejezés
2026. szept. 15.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport színlelt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • EFT
  • high frequency rTMS
  • sham frequency rTMS
A regiszteradat frissítve
2026. szeptember 24.

Ki vehet részt

Életkor
18 év – 65 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 18 feltétel megnézéseKevesebb

Ki vehet részt

  • Meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for primary methamphetamine use disorder
  • Be fluent in English and able to understand the consent form

Ki nem vehet részt

  • Medical implants contraindicating TMS (i.e., aneurysm clips or coils, stents, implanted stimulators, implanted vagus nerve or deep brain stimulators, implanted electrical devices such as pacemakers or medication pumps, electrodes for monitoring brain activity, cochlear implants for hearing, any magnetic implants, bullet fragments, any other metal device or object implanted in your body closer than 30 cm from the coil)
  • Current DSM-5 diagnosis for any illicit substance use disorder other than methamphetamine and marijuana
  • Current DSM-5 diagnosis of moderate or greater severity for alcohol and marijuana use disorder
  • In the opinion of the PI, the presence of any medical, neurological, psychiatric (e.g., psychotic or bipolar disorder), or physical condition, disease, or illness that, may: (a) compromise, interfere, limit, effect or reduce the subject's ability to complete the study; or (b) adversely impact the safety of the subject or the integrity of the data
  • History of brain surgery
  • History of an intracranial lesion or any medical or neurological diagnosis/condition associated with increased intracranial pressure (i.e., Idiopathic Intracranial Hypertension/Pseudotumor Cerebri) OR any of the following symptoms within 30 days of enrollment: headaches > 15 days/month, loss of vision or decreased vision
  • Moderate-to-severe heart disease
  • History of stroke
  • Is taking any antidepressant or antipsychotic medication at a dose above the maximum recommended dose or at a dose deemed to be potentially unsafe according to the PI; has taken any of the following medications, which are known to increase the risk of seizures, within 1 week of study enrollment; or does not agree to abstain from taking the following medications during study participation:; clozapine; chlorpromazine; bupropion; clomipramine hydrochloride; amoxapine; maprotiline hydrochloride; diphenhydramine; stimulants other than methamphetamine including the following: Dextroamphetamine and amphetamine, Dextroamphetamine, Lisdexamfetamine dimesylate, Cocaine, Methylphenidate,; tramadol; isoniazid
  • Personal history of epilepsy or seizure disorder and/or family history including a first-degree relative
  • For adolescent aged participants (18-21 only): any risk factor for neurocardiogenic syncope (history of syncope/presyncope related to noxious stimuli, anxiety, micturition, or posture)
  • Has current or recent (within 3 months of potential enrollment) suicidal ideation, suicidal behavior, homicidal ideation or a homicidal plan sufficient to raise subject safety concerns based on the following assessments according to the PI:; Structured Clinical Interview for DSM-5 (SCID-5); Columbia-Suicide Severity Rating Scale (C-SSRS) Screening - Answers YES to Questions 3, 4, 5, or 6; Assault \& homicidal danger assessment tool - Key to danger >1
  • Serious head injury with loss of consciousness
  • Impending incarceration
  • Pregnant or nursing females
  • Inability to read, write, or speak English

Helyszínek itt: Egyesült Államok

  • The University of Texas Health Science Center at HoustonHouston, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

The purpose of this study is to assess impact of repetitive transcranial magnetic stimulation (rTMS)+Episodic Future Thinking (EFT) vs. sham rTMS+EFT on delay discounting and methamphetamine (MA) demand, on vividness of future positive events during EFT training and on frequency of episodic thinking during the week following EFT training

A vizsgálat 2 csoportja

  • highfrequency rTMS+EFTA vizsgált kezelés

    Kezelés: EFT és high frequency rTMS

  • sham rTMS+EFTSzínlelt kezelés, összehasonlításként

    Kezelés: EFT és sham frequency rTMS

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
A regiszteradat frissítve
2026. szeptember 24.